Colaboración Público-Privada para el descubrimiento de Fármacos en España Santiago de Compostela 19 de Noviembre de 2009 R&D focused Oryzon is a biomarker and target discovery company with IVD & drugs for oncology and neurodegenerative diseases Robust financial situation Venture backed from 2003 >22 M € fresh cash-in achieved in 2008 5 M € income in 2007 & 6.7M € in 2008 5 consecutive years on net profits (2004-2008) Fast growing commitment acquisition of Crystax Pharmaceuticals becoming the biggest drug-discovery biotech in oncology in Spain more than 80 scientist (40 Ph.D + 20 BSCi) >22 M € R&D investment in 4 years Product oriented platforms DISCOVERY DISCOVERY PLATFORM POTENTIAL BIOMARKERS/ TARGETS THERAPY FUNCTIONAL VALIDATION PLATFORM PROTEOMIC VALIDATION PLATFORM VALIDATED TARGETS ANTIBODY DEVELOPMENT PLATFORM STRUCTURAL GENOMICS PLATFORM THERAPEUTIC BIOLOGICALS SMALL MOLECULES DIAGNOSTICS VALIDATED BIOMARKERS IVD KITS Internal Drug Discovery Capabilities (I) B2D2TM Biology Virtual Screening Fragment Screening Crystallization NMR Methods Internal Drug Discovery Capabilities (II) Calorimetry Cellular assays In vitro Binding SAR Energetics Potency in cells X-ray Biomarkers 17AAG Biacore RU CRY0165 C Slow diss. RU Fast diss. 14 12 12 GADPH 10 10 8 8 CDK4 Her2 Hsp70 Response Response c-Raf1 6 4 2 0 0 -2 -2 Medicinal Chemistry 20 50 80 Time Mechanism 4 2 -10 Structure-based drug design 6 110 140-20 s Kinetics 0 20 40 Time 60 80 s Small molecules Research at Oryzon: A young and successful enterprise Early 2008 Target elucidation Mid 2008 Start of the Medicinal Chemistry Effort End 2008 Crystax acquisition Today….. Full drug discovery engine……over 30 people Fragment screening capabilities HTS facilities Biochemical assays labs Medicinal Chemistry Pharmacokinetics and metabolism In vivo Pharmacology Toxicology 5 Drug Discovery programs in progress EL EXITO DE LAS COLABORACIONES ES CLAVE PARA SER UNA BIOTECH EXITOSA